Tilray Jumps on Study of Cannabis for Breast Cancer Side Effects

By: Gregory Calderone

Tilray Inc. shares jumped as much as 14% after announcing it successfully imported medical cannabis into the U.S. in support of a clinical trial studying its efficacy in treating patients with disorders caused by breast cancer treatments.

The study will focus on patients suffering from taxane-induced peripheral neuropathy, or TIPN, secondary to treatment with paclitaxel or docetaxel. TIPN affects more than 67% of women undergoing breast cancer treatment, the company said.

To read more:

Leave a Reply

Your email address will not be published. Required fields are marked *